Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: new + therapy + death  Related to the article below (Last Update: 8/5/2008)

Expansion of ARV programmes could reduce new HIV infections
Africa Science News Service, Kenya -
A Canadian study by the BC Centre for Excellence in HIV/AIDS (BC-CfE) reveals the dramatic impact that increased coverage with HIV therapy could have in ...
AIDS denial condemns S. Africans to avoidable death
ABC Science Online, Australia -
The reality is that AIDS is a new disease caused by HIV and that the modern anti-viral drugs are saving lives. But these drugs are not freely available ...
More drugs, less couch
Minneapolis Star Tribune, MN -
A new study finds a significant decline in psychotherapy practiced by US psychiatrists. The expanded use of pills and insurance policies that favor short ...
MDC Spokesman Nozzolio Dies
Hartford Courant, United States -
Nozzolio performed a solo show Saturday morning in New Haven. He collapsed on the street that afternoon, Wertz said. The cause of death was still being ...
Science and Medicine: Complicated Grief
Washington Post, United States -
There is evidence that those with complicated grief have an even higher risk of being diagnosed with a new illness after the death of a loved one. ...
Craig W. Philips Takes Helm at CTI
FOXBusiness - 25 minutes ago
He began his career with Bristol Myers, where he worked in a variety of therapy areas including oncology, cardiology, and CNS. ...CTIC - OTC:CMTX
Lowering Cholesterol Early In Life Could Save Lives
Science Daily (press release) -
... in death and disability from heart disease in patients treated with statins, 70% of patients have cardiac events while on statin therapy. Promising new ...
Vaccine failures shake up HIV research
Chemistry World, UK -
Moreover, new drugs are very expensive to introduce because they are almost always considered as part of a cocktail therapy, making clinical trials complex ...

New York Daily News
FBI Used DNA to Link
Wall Street Journal Blogs, NY -
A crisis counselor who met with Dr. Ivins in weekly therapy sessions for the past six months described a man who was preparing for an angry confrontation ...
AssociatedPress
Case against anthrax scientist circumstantial, source says Dallas Morning News
Records key to anthrax mystery USA Today
CNN - San Francisco Chronicle
all 5,269 news articles »
Genetic testing brings new hopes, hard choices
Boston Globe, United States - Aug 3, 2008
The heart gene tests allow "predictive medicine and preventative therapy," said Dr. Christine Seidman, a cardiologist and researcher at Harvard Medical ...
Source: Google News

CLINICAL TRIALS: Gene Therapy Death Prompts Review of Adenovirus Vector -
E Marshall - Science, 1999 - sciencemag.org
... the edge of the envelope." Beaudet and Caskey are both testing a new, "gutless"
adenovirus vector ... Gelsinger's death "did some damage to gene therapy, and it ...

Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in … -
A May, L Gossner, O Pech, A Fritz, E G?nter, G … - European Journal of Gastroenterology & Hepatology, 2002 - eurojgh.com
... in 12 of these cases the cause of death was not ... phase and intermediate results of
local endoscopic therapy indicate that this new therapeutic strategy can ...

Control of programmed cell death in normal and leukemic cells: new implications for therapy. -
L Sachs, J Lotem - Blood, 1993 - ncbi.nlm.nih.gov
Blood. 1993 Jul 1;82(1):15-21. Click here to read Control of programmed cell death
in normal and leukemic cells: new implications for therapy. ...

New Guidelines to Evaluate the Response to Treatment in Solid Tumors -
P Therasse, SG Arbuck, EA Eisenhauer, J Wanders, … - jnci, 2000 - jnci.oxfordjournals.org
... without the appearance of new lesions *. ... disease progression, even after discontinuation
of treatment. ... define early progression, early death, and inevaluability ...

IKK/NF-?B signaling: balancing life and death?a new approach to cancer therapy -
JL Luo, H Kamata, M Karin - Journal of Clinical Investigation, 2005 - pubmedcentral.nih.gov
... Copyright ? 2005, American Society for Clinical Investigation. IKK/NF-?B signaling:
balancing life and death ? a new approach to cancer therapy. ...

[PDF] … by antagonism of ADAM 12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy -
M Asakura, M Kitakaze, S Takashima, Y Liao, F … - Nature Medicine, 2002 - cardio.bjmu.edu.cn
... in chronic heart failure or sudden cardiac death 2 . Elucidation ... biol- ogy, and may
lead to new strategies for ... can be beneficial for the treatment of chronic ...
-

Researchers and regulators reflect on first gene therapy death. -
T Hollon - American Journal of Ophthalmology, 2000 - Elsevier
... DOI (Opens New Window) Copyright ? 2000 Elsevier Science Inc. All rights reserved.
Abstracts. Researchers and regulators reflect on first gene therapy death. ...

… and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid … -
M Crisby, G Nordin-Fredriksson, PK Shah, J Yano, J … - Circulation, 2001 - Am Heart Assoc
... Tobert J. Lipid lowering therapy for patients ... of coronary heart disease: new evidence,
implications ... myocardial infarction, sudden ischemic death, and crescendo ...

Cardiac Resynchronization and Death From Progressive Heart Failure A Meta-analysis of Randomized … -
DJ Bradley, EA Bradley, KL Baughman, RD Berger, H … - JAMA, 2003 - Am Med Assoc
... have heart failure, with 550 000 new patients diagnosed ... 1 Despite substantial advances
in drug therapy, 2 heart ... 3 Heart failure generally leads to death by 1 ...

Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and … -
M Gershanovich, HA Chaudri, D Campos, H Lurie, A … - Annals of Oncology, 1998 - Springer
... e?cacy, safety and tolerability of a new aromatase inhibitor ... time to progression
and time to treatment failure ... 36% reduction in the risk of death compared with ...

Source: Google Scholar

Penn Researchers Identify New Combination Therapy That Promotes Cancer Cell Death
Researchers at the University of Pennsylvania School of Medicine identified a combination therapy as a way to sensitize resistant human cancer cells to a treatment currently being tested in clinical trials. They propose that the therapy may help to selectively eliminate cancer cells while leaving healthy cells intact, providing a cancer treatment with fewer side effects. The Penn team reports their findings in the July issue of Cancer Cell.
To test the ability of the combined therapy in treating cancerous tumors, senior author Wafik S. El-Deiry, MD, PhD, and colleagues administered TRAIL, a tumor necrosis factor, and sorafenib, an inhibitor currently used to treat renal cancer, to mice with colon carcinomas. The sorafenib and TRAIL therapy reduced the size of tumors in mice with few side effects, demonstrating the potential effectiveness of the combined treatment on human colon cancers. "Cancer cells will do whatever it takes to survive in harsh environments," explains El-Deiry, Professor of Medicine, Genetics, and Pharmacology. To kill hearty cancer cells, El-Deiry and other scientists are working on ways to alter them so they become more susceptible to cell death.

In ongoing clinical trials, doctors are giving cancer patients extra doses of TRAIL (TNF-a-related apoptosis-inducing ligand), a molecule naturally produced by the body's immune system that promotes cell death, to help kill off cancer cells. While TRAIL-based therapy is promising, over 50 percent of all cancer cells show resistance to TRAIL. To create a more potent form of targeted cancer therapy, El-Deiry's research team began searching for ways to reverse TRAIL resistance in cancer cells.

Recently, El-Deiry's research group found that TRAIL-resistant cells avoid death by producing "survival" proteins called cIAP2 and Mcl-1. The oncogene c-Myc in part hampers a cancer cell's survival strategy by blocking the function of an intermediate protein that oversees cIAP2 and Mcl-1 production. Without these survival proteins, cancer cells are unable to resist the death initiated by TRAIL.

In search of drugs that perform a similar cancer-cell death function to c-Myc, El-Deiry's lab turned to sorafenib, which is also being considered for the treatment of a variety of cancers. Like c-Myc, the researchers found that sorafenib blocked the intermediate and survival proteins when combined with TRAIL, causing TRAIL-resistant colon and lung cancer cell lines to die.

"Our findings are exciting because TRAIL in combination with sorafenib appears to be much less toxic than current chemotherapy drugs," explains El-Deiry. "Plus, sorafenib is already available in a pill form."

While enthusiastic about his recent findings, El-Deiry notes sorafenib may be working to increase cell sensitivity to TRAIL through more biochemical pathways than the intermediate alone.

"The ability of sorafenib to work through multiple pathways may be beneficial to cancer treatments because cancer may be altering multiple targets," says El-Deiry.

In the future, El-Deiry plans to explore additional pathways sorafenib may be working through to increase TRAIL sensitivity and to compare the effectiveness of other drugs.

"In addition to proposing a combination therapy that's rational, non-toxic, and effective in preclinical trials, our findings open up new avenues of molecular exploration for designing targeted anti-cancer therapies," said El-Deiry.

Co-authors include M. Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, John P. Plastaras, Wenge Wang, Zhaoyu Jin, Yingqiu Y. Liu, David T. Dicker, and Keith T. Flaherty from Penn; Charles D. Smith from Pennsylvania State University; Jianhua Ling and Paul J. Chiao from the University of Texas MD Anderson Cancer Center.
The National Cancer Institute and the Littlefield-AACR award provided funding for this work.

PENN Medicine is a $3.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.

http://www.uphs.upenn.edu
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.